 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678» |
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P1 trial: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers (EUDRACT) - Apr 5, 2021
P1, N=16, Not yet recruiting, Sponsor: Ascil Australia Pty LTD
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN) () - Mar 27, 2021 - Abstract #ENETS2021ENETS_241;
This suggests that physicians provided an adequate level of information at diagnosis. The absence of deterioration in QoL at M6 indicates the good tolerability of LAN.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS) () - Mar 27, 2021 - Abstract #ENETS2021ENETS_240;
The option for independent injection, which can increase patient autonomy and may reduce COVID-19 risk, is associated with a lower burden on healthcare resources and substantial cost savings. These potential benefits should be considered alongside patient experience in evaluating pandemic-enforced practices that may be beneficial to adopt long-term.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] The role of somatostatin receptor scintigraphy in predicting treatment response of somatostatin analogues in pancreatic neuroendocrine tumors () - Mar 27, 2021 - Abstract #ENETS2021ENETS_239;
All patients received SSA mono therapy as first line treatment, such as octreotide LAR or lanreotide Autogel. Lower HTB and grade are associated with good response to SSA treatment, SSA situation does not necessarily imply response to SSA therapy.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] CLARINET FORTE: Characterization of Pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with Lanreotide Autogel (LAN) 120 mg every 14 days (q14d) () - Mar 27, 2021 - Abstract #ENETS2021ENETS_238;
P2
A relationship between LAN exposure from the q14d regimen and efficacy was established. There was no relationship between LAN exposure and adverse events of interest.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed: A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (clinicaltrials.gov) - Mar 22, 2021
P2, N=114, Active, not recruiting, Sponsor: University of Washington
There was no relationship between LAN exposure and adverse events of interest. Recruiting --> Active, not recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, P3 data, Journal: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). (Pubmed Central) - Mar 17, 2021
P3
Recruiting --> Active, not recruiting Lanreotide autogel was non-inferior to lanreotide 40 mg PR in Chinese patients with active acromegaly after 32 weeks of treatment.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
HEOR: Quality of Life Maintained After Dose Doubling of Lanreotide Autogel in #NeuroendocrineTumors. https://t.co/kaQaPqiBHL via @targetedonc (Twitter) - Mar 2, 2021
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Mar 2, 2021
P3, N=77, Completed, Sponsor: Ipsen
Lanreotide autogel was non-inferior to lanreotide 40 mg PR in Chinese patients with active acromegaly after 32 weeks of treatment. Active, not recruiting --> Completed
- || cimdelirsen (IONIS-GHR-LRx) / Ionis
Enrollment status: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - Feb 21, 2021
P2, N=60, Enrolling by invitation, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results () - Feb 12, 2021 - Abstract #ENETS2021ENETS_18;
P2
PFS with LAN 120 mg q14 days in patients with panNETs or midgut NETs (progressive on LAN q28 days) was promising, with no new safety signals or QoL deterioration. In the panNET cohort, PFS was longer in patients with Ki67 ≤10%.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors. An international double-blind, placebo-controlled randomized phase II. Prodige 31 REMINET. A FFCD study () - Feb 12, 2021 - Abstract #ENETS2021ENETS_12;
In the panNET cohort, PFS was longer in patients with Ki67 ≤10%. The encouraging results of lanreotide autogel 120 mg as maintenance treatment after L1 in aggressive G1/2 DP-NET should be further confirmed.
- Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] Clinical Presentation and Management of Patients With Acromegaly at a University Hospital (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_1560;
Twelve patients were subsequently excluded from this analysis - nine patients who had been recently diagnosed and were awaiting surgical treatment as well as three patients who had been lost to follow-up. The study sample (n=60) included forty females patients (67%).
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Use of Oral Concomitant Medications in Patients With Acromegaly (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_1552;
P3, P4
In this analysis, most patients with acromegaly receiving LAN, regardless of prior therapy, used ≥1 concomitant oral medication. An awareness of the ongoing burden of comorbidities requiring oral medications should help physicians in managing acromegaly.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion date, Trial initiation date, Trial primary completion date, HEOR: PREF-NET: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (clinicaltrials.gov) - Jan 31, 2021
P=N/A, N=120, Not yet recruiting, Sponsor: Ipsen
An awareness of the ongoing burden of comorbidities requiring oral medications should help physicians in managing acromegaly. Trial completion date: Feb 2021 --> Sep 2021 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Feb 2021 --> Sep 2021
- || cimdelirsen (IONIS-GHR-LRx) / Ionis
Trial completion date, Trial primary completion date: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - Jan 11, 2021
P2, N=60, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Feb 2021 --> Sep 2021 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Feb 2021 --> Sep 2021 Trial completion date: Jan 2021 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2023
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. (Pubmed Central) - Jan 9, 2021
P3
In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1-2, Ki-67 < 10%)...These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs. This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Retrospective data, Journal: Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. (Pubmed Central) - Jan 6, 2021
P3
This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis. The use of predictive factors at baseline and week 12 of treatment could inform clinical expectations of the long-term efficacy of lanreotide autogel.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
New trial: AIM-NETs: Asian Investigation of Lanreotide Autogel (clinicaltrials.gov) - Jan 5, 2021
P, N=95, Recruiting, Sponsor: Asan Medical Center
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical: Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg With Prolonged Administration in Indolent #NeuroendocrineTumors https://t.co/gREG77KR3v via @OncJournal @DrBonillaOnc #LetsTalkAboutNETs (Twitter) - Jan 5, 2021
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial, Combination therapy, Metastases: NA NA (EUDRACT) - Dec 17, 2020
P2, N=20, Ongoing, Sponsor: FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). (Pubmed Central) - Dec 17, 2020
The use of predictive factors at baseline and week 12 of treatment could inform clinical expectations of the long-term efficacy of lanreotide autogel. Nurses preferred the user experience of the LAN new syringe compared with the octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe.
- Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_295;
P1/2
In a population of GEP-NET patients, progressing on a median of 2 prior therapies, including prior somatostatin analogue therapy, a minority of whom had PD-L1 expressing tumors, the combination of lanreotide and pembrolizumab produced stable disease in approximately 40% of patients. No new safety signals were identified.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion date, Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Dec 8, 2020
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
No new safety signals were identified. Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021
- |||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, HEOR: PREF-NET: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (clinicaltrials.gov) - Dec 1, 2020
P, N=120, Not yet recruiting, Sponsor: Ipsen
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 12, 2020
P1/2, N=22, Active, not recruiting, Sponsor: Duke University
Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021 Trial completion date: Sep 2020 --> Jun 2021 | Trial primary completion date: Sep 2020 --> Jun 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date: A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (clinicaltrials.gov) - Nov 4, 2020
P2, N=123, Recruiting, Sponsor: University of Washington
Trial completion date: Sep 2020 --> Jun 2021 | Trial primary completion date: Sep 2020 --> Jun 2021 Trial primary completion date: Apr 2020 --> Mar 2021
- || paltusotine (CRN00808) / Crinetics
Trial completion: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (clinicaltrials.gov) - Nov 4, 2020
P2, N=13, Completed, Sponsor: Crinetics Pharmaceuticals Inc.
Trial primary completion date: Apr 2020 --> Mar 2021 Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] Patient Experience with Somatostatin Analog Treatments for Neuroendocrine Tumors: Insight from Qualitative Interviews (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_69;
Octreotide LAR and lanreotide depot are both somatostatin analogs (SSAs) recommended to treat patients with NETs. Our qualitative interview data allows characterization of patient experiences with lanreotide or octreotide and highlights differences in treatment attributes.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_26;
P2
Our qualitative interview data allows characterization of patient experiences with lanreotide or octreotide and highlights differences in treatment attributes. LAN 120 mg q14 days in progressive midgut NETs provided encouraging PFS and DCR efficacy results, with an acceptable safety profile.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_25;
P2
LAN 120 mg q14 days in progressive midgut NETs provided encouraging PFS and DCR efficacy results, with an acceptable safety profile. LAN 120 mg q14 days in progressive panNETs produced no new safety signals; patients with Ki67 ≤10% appear to benefit most from the increased dose.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Real-World Observational Study of Somatostatin Analogs and Rescue Medication Use for Neuroendocrine Tumors in Canada (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_19;
BACKGROUND: Two long-acting somatostatin analogs (SSAs), octreotide longacting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available for the management of neuroendocrine tumors (NETs)... For patients requiring rescue medication, switching SSAs significantly reduced rescue medication claims, suggesting optimal use of long-acting SSAs may include switching between agents.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] In the Current COVID Reality, CAN Independent Injection of Somatostatin Snalogues Lead to Greater Health Savings? a Budget IMPACT Analysis in the UK () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_394;
The COVID-19 pandemic has highlighted the potential cost savings associated with the increased patient autonomy offered by independent injection, during which time it may help to ease pressure on healthcare resources. Any pandemic-enforced increase may, if adopted long-term, translate into substantial ongoing savings.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, HEOR: OPERA: Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (clinicaltrials.gov) - Aug 27, 2020
P=N/A, N=115, Completed, Sponsor: Ipsen
Any pandemic-enforced increase may, if adopted long-term, translate into substantial ongoing savings. Recruiting --> Completed
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal, Real-World Evidence: Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. (Pubmed Central) - Aug 7, 2020
As per published guidelines, SSAs are common in first-line systemic intervention, but dose escalations and dosing deviations outside of the label are noted for symptom control. Nevertheless, oncologists must weigh the implications of the use of above-label dosing of SSAs to manage and treat patients with metastatic NET within a value-based care framework.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (On-Demand) - Aug 6, 2020 - Abstract #ESMO2020ESMO_2876;
P2
Funding: Ipsen. Clinical trial identification: NCT02651987.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm. (Pubmed Central) - Jul 29, 2020
This is the first prospective study evaluating the efficacy of somatostatin analogues in MEN1-related pNETs. These findings highlight that lanreotide autogel is effective as anti-proliferative therapy in MEN1-related pNETs <2cm, suggesting the use of these compounds to arrest the development of tumor lesions as well as to delay or avoid pancreatic surgery.
- [VIRTUAL] Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1949;
P2/3
Methods The aim of this academic randomized, double-blind, placebo-controlled study was to evaluate lanreotide autogel (LAN) as maintenance treatment after 1st line treatment (L1) in aggressive G1-G2 WDDP NET...L1 therapy consisted of temozolomide-based (52.9%), dacarbazine-based (18.7%), streptozotocin-based (13.3%), oxaliplatin-based (11.3%) or sunitinib (3.8%)...Funding: Ipsen. Clinical trial identification: NCT02288377.
- temozolomide / Generic mfg., Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1523;
P2
Funding: Ipsen. Clinical trial identification: NCT02698410; EudraCT: 2014-005579-10.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion date, Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - Jul 9, 2020
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Clinical trial identification: NCT02698410; EudraCT: 2014-005579-10. Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: Apr 2020 --> Jan 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 7, 2020
P1/2, N=22, Active, not recruiting, Sponsor: Duke University
Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: Apr 2020 --> Jan 2021 Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Sep 2020
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies. (Pubmed Central) - Jul 2, 2020
With collaboration, a new syringe was developed to meet the needs of patients, caregivers and HCPs, whilst ensuring lanreotide was delivered effectively and safely. These studies highlight the importance of involving patients, caregivers and HCPs in clinical evaluation studies to develop medical products that address their concerns and meet their needs.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Metastases: Community-based Neuroendocrine Tumor (NET) Research Study (clinicaltrials.gov) - Jun 26, 2020
P=N/A, N=100, Completed, Sponsor: Ipsen
These studies highlight the importance of involving patients, caregivers and HCPs in clinical evaluation studies to develop medical products that address their concerns and meet their needs. Active, not recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
[VIRTUAL] An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1511;
Active, not recruiting --> Completed The PRESTO study showed that nurses preferred the user experience of the LAN new syringe over the current OCT LAR syringe across all attributes tested.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal, HEOR: Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. (Pubmed Central) - Jun 4, 2020
Patients with NET experience a large symptom burden that varies daily. A decrease in physical symptoms on QoL surveys suggests an effect from daily app-based monitoring or journaling, which may reduce recall bias and benefit the patient's experience of symptoms.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change: Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment (clinicaltrials.gov) - Jun 2, 2020
P2, N=5, Terminated, Sponsor: Ipsen
A decrease in physical symptoms on QoL surveys suggests an effect from daily app-based monitoring or journaling, which may reduce recall bias and benefit the patient's experience of symptoms. N=20 --> 5
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Journal: Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pubmed Central) - May 23, 2020
Current guidelines focus only on the monitoring of 5-hydroxyindoleacetic acid (5-HIAA) in the diagnosis and management of functional neuroendocrine tumors with carcinoid syndrome. The current post hoc analysis of patients with nonfunctional enteropancreatic neuroendocrine tumors in the CLARINET study demonstrated that measuring and following both 5-HIAA and chromogranin A as biomarkers of disease progression may be useful in the management of patients with nonfunctional neuroendocrine tumors.
- || Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Observational data, Retrospective data, Review, Journal: COMPARATIVE EFFICACY OF MEDICAL TREATMENT FOR ACROMEGALY: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS OF INTEGRATED RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES. (Pubmed Central) - May 21, 2020
Our analysis suggested that the combination of data from observational studies and randomized trials in network meta-analysis was feasible. The findings of this network meta-analysis provided robust evidence supporting the current guidelines in treatment strategy for acromegaly.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. (Pubmed Central) - May 19, 2020
The findings of this network meta-analysis provided robust evidence supporting the current guidelines in treatment strategy for acromegaly. The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.
- ||| Xermelo (telotristat etiprate) / Lexicon Pharma, Ipsen, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal, Adverse events: Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect. (Pubmed Central) - May 16, 2020
Of these, 23 received short-acting SSA for worsening diarrhea, 96 had intensification of antidiarrheal and 1 got telotristat ethyl...Although SAAs are used to treat diarrhea, paradoxically they can worsen diarrhea secondary to EPI. Early recognition and diagnosis of this under-diagnosed and under-reported side effect of SAAs, such as EPI, can improve not only diarrhea and weight loss in these patients but also can reduce cost of using short-acting SAAs and antidiarrheal.